Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemdisiran in Adult IgA Nephropathy
NCT03841448Phase 2Terminated
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- Mar 2022
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 9
01
Overview
A Phase 2 trial of cemdisiran in IgA nephropathy (IgAN), sponsored by Alnylam Pharmaceuticals. Started Sep 2019; status: terminated.
02
Drugs
cemdisiran
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT03841448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03841448.